Evaluating Anti-Tobacco Message Effectiveness Among Lesbian, Gay, Bisexual, and Transgender Young Adults
NCT ID: NCT05393869
Last Updated: 2023-12-26
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
2849 participants
INTERVENTIONAL
2021-04-14
2022-11-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. Identify absolute and relative risk anti-tobacco messages that effectively communicate polytobacco risks to lesbian, gay, bisexual, transgender (LGBT) young adults.
Participants view anti-tobacco messages and rate them for perceived effectiveness and reactance.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AR-Quit
Participants view messages with absolute risk and quit statements
Health communications
Participants are assigned to view health communications with risk and efficacy statements.
AR-Switch
Participants view messages with absolute risk and switch statements
Health communications
Participants are assigned to view health communications with risk and efficacy statements.
AR-Combination
Participants view messages with absolute risk and combination quit+switch statements
Health communications
Participants are assigned to view health communications with risk and efficacy statements.
RR-Quit
Participants view messages with comparative risk and quit statements
Health communications
Participants are assigned to view health communications with risk and efficacy statements.
RR-Switch
Participants view messages with comparative risk and switch statements
Health communications
Participants are assigned to view health communications with risk and efficacy statements.
RR-Combination
Participants view messages with comparative risk and combination quit+switch statements
Health communications
Participants are assigned to view health communications with risk and efficacy statements.
Control
Participants view FDA regulatory messages
Health communications
Participants are assigned to view health communications with risk and efficacy statements.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Health communications
Participants are assigned to view health communications with risk and efficacy statements.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Live in the United States
At least 50% of the sample also:
* Are susceptible to multiple nicotine and tobacco product use (i.e., have used combustible tobacco or e-cigarettes at least once)
18 Years
35 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Ohio State University Comprehensive Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Joanne Patterson
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joanne G Patterson, PhD MPH MSW
Role: PRINCIPAL_INVESTIGATOR
Ohio State University Comprehensive Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
The Jamesline
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2022-02543
Identifier Type: REGISTRY
Identifier Source: secondary_id
OSU-20427
Identifier Type: -
Identifier Source: org_study_id